AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing a botulinum toxin complex for multiple therapeutic indications, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY. The event is scheduled for September 11, 2024.
Key points:
- Marc Forth, AEON's President and CEO, will present a corporate overview at 1:30 PM ET
- One-on-one meetings with institutional investors will be available
- A live webcast of the conference event will be accessible through the conference host
This participation provides AEON an opportunity to showcase its progress and engage with potential investors, potentially impacting its market position and future funding prospects.
AEON Biopharma (NYSE: AEON), un'azienda biofarmaceutica in fase clinica che sviluppa un complesso di tossina botulinica per molteplici indicazioni terapeutiche, ha annunciato la sua partecipazione al 26° Convegno Annuale Global Investment di H.C. Wainwright a New York, NY. L'evento è programmato per il 11 settembre 2024.
Punti chiave:
- Marc Forth, Presidente e CEO di AEON, presenterà una panoramica aziendale alle 13:30 ET
- Incontri individuali con investitori istituzionali saranno disponibili
- Una diretta web del convegno sarà accessibile tramite l'organizzatore dell'evento
Questa partecipazione offre ad AEON l'opportunità di mostrare i propri progressi e interagire con potenziali investitori, influenzando potenzialmente la sua posizione di mercato e le prospettive di finanziamento future.
AEON Biopharma (NYSE: AEON), una compañía biofarmacéutica en etapa clínica que desarrolla un complejo de toxina botulínica para múltiples indicaciones terapéuticas, ha anunciado su participación en el 26° Conferencia Anual Global de Inversiones de H.C. Wainwright en Nueva York, NY. El evento está programado para el 11 de septiembre de 2024.
Puntos clave:
- Marc Forth, Presidente y CEO de AEON, presentará una visión general de la empresa a la 1:30 PM ET
- Se ofrecerán reuniones individuales con inversionistas institucionales
- Una transmisión en vivo del evento de la conferencia será accesible a través del anfitrión de la conferencia
Esta participación brinda a AEON la oportunidad de mostrar sus avances e interaccionar con potenciales inversionistas, lo que podría influir en su posición en el mercado y en las perspectivas de financiamiento futuro.
AEON Biopharma (NYSE: AEON)은 여러 치료 적응증을 위한 보툴리누스 독소 복합체를 개발하는 임상 단계의 바이오 제약 회사로, 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 11일로 예정되어 있습니다.
주요 사항:
- AEON의 사장 겸 CEO인 Marc Forth가 오후 1시 30분(ET)에 회사 개요를 발표합니다
- 기관 투자자와의 일대일 미팅이 제공될 예정입니다
- 회의 이벤트의 생중계는 회의 주최자를 통해 접근할 수 있습니다
이번 참여는 AEON이 자신의 발전 상황을 알리고 잠재적 투자자와 교류할 기회를 제공하여, 시장 지위와 향후 자금 조달 가능성에 영향을 줄 수 있습니다.
AEON Biopharma (NYSE: AEON), une entreprise biopharmaceutique en phase clinique développant un complexe de toxine botulinique pour plusieurs indications thérapeutiques, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright à New York, NY. L'événement est prévu pour le 11 septembre 2024.
Points clés :
- Marc Forth, Président et CEO d'AEON, présentera un aperçu de l'entreprise à 13h30 ET
- Des réunions individuelles avec des investisseurs institutionnels seront disponibles
- Une diffusion en direct de l'événement de la conférence sera accessible par l'intermédiaire de l'hôte de la conférence
Cette participation offre à AEON l'opportunité de mettre en avant ses progrès et d'engager des discussions avec des investisseurs potentiels, ce qui pourrait influencer sa position sur le marché et ses perspectives de financement futur.
AEON Biopharma (NYSE: AEON), ein biopharmazeutisches Unternehmen in der klinischen Phase, das einen Botulinumtoxin-Komplex für mehrere therapeutische Indikationen entwickelt, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright in New York, NY, angekündigt. Die Veranstaltung ist für den 11. September 2024 geplant.
Wichtige Punkte:
- Marc Forth, Präsident und CEO von AEON, wird um 13:30 Uhr ET eine Unternehmensübersicht präsentieren
- Einzelgespräche mit institutionellen Investoren werden verfügbar sein
- Ein Live-Stream der Konferenzveranstaltung wird über den Gastgeber der Konferenz zugänglich sein
Diese Teilnahme bietet AEON die Möglichkeit, seine Fortschritte zu präsentieren und mit potenziellen Investoren in Kontakt zu treten, was potenziell seine Marktposition und zukünftige Finanzierungsmöglichkeiten beeinflussen könnte.
- None.
- None.
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, AEON’s President and Chief Executive Officer, will present a corporate overview on Wednesday, September 11, 2024 at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.
Mr. Forth will also participate in one-on-one meetings, and institutional investors interested in meeting during the conference should contact their H.C. Wainwright representative.
A live webcast of the conference event will be available through the conference host.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. AEON undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of AEON in general, see AEON’s current and future filings with the U.S. Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
FAQ
When is AEON Biopharma presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for AEON Biopharma at the investment conference?
Will AEON Biopharma be available for one-on-one meetings at the conference?
How can investors access AEON Biopharma's presentation at the conference?
What is the main focus of AEON Biopharma's research?
